The impact of benralizumab and dupilumab on exhaled volatile organic compound profiles of severe asthma patients – a preliminary analysis

Authors:

Abstract
No abstract available
Funding Information
  • AstraZeneca
  • Sanofi

This publication has 52 references indexed in Scilit: